These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 11420084

  • 1. Precipitated cannabinoid withdrawal is reversed by Delta(9)-tetrahydrocannabinol or clonidine.
    Lichtman AH, Fisher J, Martin BR.
    Pharmacol Biochem Behav; 2001; 69(1-2):181-8. PubMed ID: 11420084
    [Abstract] [Full Text] [Related]

  • 2. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice.
    Lichtman AH, Sheikh SM, Loh HH, Martin BR.
    J Pharmacol Exp Ther; 2001 Sep; 298(3):1007-14. PubMed ID: 11504797
    [Abstract] [Full Text] [Related]

  • 3. Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids.
    Janoyan JJ, Crim JL, Darmani NA.
    Pharmacol Biochem Behav; 2002 Sep; 71(1-2):155-62. PubMed ID: 11812518
    [Abstract] [Full Text] [Related]

  • 4. Reversal of cannabinoids (delta9-THC) by the benzoflavone moiety from methanol extract of Passiflora incarnata Linneaus in mice: a possible therapy for cannabinoid addiction.
    Dhawan K, Kumar S, Sharma A.
    J Pharm Pharmacol; 2002 Jun; 54(6):875-81. PubMed ID: 12079005
    [Abstract] [Full Text] [Related]

  • 5. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A.
    Darmani NA.
    Neuropsychopharmacology; 2001 Feb; 24(2):198-203. PubMed ID: 11120402
    [Abstract] [Full Text] [Related]

  • 6. Rimonabant-induced Delta9-tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs.
    Stewart JL, McMahon LR.
    J Pharmacol Exp Ther; 2010 Jul; 334(1):347-56. PubMed ID: 20375197
    [Abstract] [Full Text] [Related]

  • 7. Discriminative stimulus effects of the cannabinoid antagonist, SR 141716A, in delta -sup-9-tetrahydrocannabinol-treated rhesus monkeys.
    McMahon LR, France CP.
    Exp Clin Psychopharmacol; 2003 Nov; 11(4):286-93. PubMed ID: 14599262
    [Abstract] [Full Text] [Related]

  • 8. Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist.
    Tai S, Nikas SP, Shukla VG, Vemuri K, Makriyannis A, Järbe TU.
    Psychopharmacology (Berl); 2015 Aug; 232(15):2751-61. PubMed ID: 25772338
    [Abstract] [Full Text] [Related]

  • 9. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.
    McMahon LR.
    Psychopharmacology (Berl); 2006 Oct; 188(3):306-14. PubMed ID: 16953389
    [Abstract] [Full Text] [Related]

  • 10. Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol.
    Hutcheson DM, Tzavara ET, Smadja C, Valjent E, Roques BP, Hanoune J, Maldonado R.
    Br J Pharmacol; 1998 Dec; 125(7):1567-77. PubMed ID: 9884086
    [Abstract] [Full Text] [Related]

  • 11. Effects of SR 141716A after acute or chronic cannabinoid administration in dogs.
    Lichtman AH, Wiley JL, LaVecchia KL, Neviaser ST, Arthur DB, Wilson DM, Martin BR.
    Eur J Pharmacol; 1998 Sep 18; 357(2-3):139-48. PubMed ID: 9797029
    [Abstract] [Full Text] [Related]

  • 12. Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew.
    Darmani NA.
    Pharmacol Biochem Behav; 2001 Sep 18; 69(1-2):239-49. PubMed ID: 11420092
    [Abstract] [Full Text] [Related]

  • 13. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
    McMahon LR, Koek W.
    Eur J Pharmacol; 2007 Aug 13; 569(1-2):70-6. PubMed ID: 17553486
    [Abstract] [Full Text] [Related]

  • 14. CB1 receptor antagonist precipitates withdrawal in mice exposed to Delta9-tetrahydrocannabinol.
    Cook SA, Lowe JA, Martin BR.
    J Pharmacol Exp Ther; 1998 Jun 13; 285(3):1150-6. PubMed ID: 9618417
    [Abstract] [Full Text] [Related]

  • 15. Pharmacological evaluation of aerosolized cannabinoids in mice.
    Lichtman AH, Peart J, Poklis JL, Bridgen DT, Razdan RK, Wilson DM, Poklis A, Meng Y, Byron PR, Martin BR.
    Eur J Pharmacol; 2000 Jul 07; 399(2-3):141-9. PubMed ID: 10884513
    [Abstract] [Full Text] [Related]

  • 16. SR 141716 (Rimonabant) precipitates withdrawal in marijuana-dependent mice.
    Wilson DM, Varvel SA, Harloe JP, Martin BR, Lichtman AH.
    Pharmacol Biochem Behav; 2006 Sep 07; 85(1):105-13. PubMed ID: 16934319
    [Abstract] [Full Text] [Related]

  • 17. (R)-Methanandamide and delta9-tetrahydrocannabinol-induced operant rate decreases in rats are not readily antagonized by SR-141716A.
    Järbe TU, Lamb RJ, Liu Q, Makriyannis A.
    Eur J Pharmacol; 2003 Apr 11; 466(1-2):121-7. PubMed ID: 12679148
    [Abstract] [Full Text] [Related]

  • 18. Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: antagonist effects of SR 141716A.
    Vivian JA, Kishioka S, Butelman ER, Broadbear J, Lee KO, Woods JH.
    J Pharmacol Exp Ther; 1998 Aug 11; 286(2):697-703. PubMed ID: 9694923
    [Abstract] [Full Text] [Related]

  • 19. Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Delta(9)-tetrahydrocannabinol in C57BL/6J mice.
    McMahon LR, Ginsburg BC, Lamb RJ.
    Psychopharmacology (Berl); 2008 Jul 11; 198(4):487-95. PubMed ID: 17673980
    [Abstract] [Full Text] [Related]

  • 20. Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol.
    DeLong GT, Wolf CE, Poklis A, Lichtman AH.
    Drug Alcohol Depend; 2010 Nov 01; 112(1-2):126-33. PubMed ID: 20619971
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.